What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis?

被引：0
|
作者：
Simon Travis
机构：
[1] Consultant Gastroenterologist and Clinical Director of the Gastroenterology Unit,
[2] John Radcliffe Hospital,undefined
来源：
Nature Clinical Practice Gastroenterology & Hepatology | 2005年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：564 / 565
页数：1
相关论文
共 50 条
  • [1] What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis?
    Travis, S
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2005, 2 (12): : 564 - 565
  • [2] The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine
    Frieri, Giuseppe
    Galletti, Brigida
    Di Ruscio, Mirko
    Tittoni, Rachele
    Capannolo, Annalisa
    Serva, Donatella
    Latella, Giovanni
    Sollima, Laura
    Leocata, Pietro
    Necozione, Stefano
    Frieri, Rosamarie
    Viscido, Angelo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2017, 10 (10) : 749 - 759
  • [3] Is once-daily dosing of mesalazine effective for maintenance of remission in patients with ulcerative colitis?
    Chris SJ Probert
    Nature Clinical Practice Gastroenterology & Hepatology, 2008, 5 : 596 - 597
  • [4] Is once-daily dosing of mesalazine effective for maintenance of remission in patients with ulcerative colitis?
    Probert, Chris S. J.
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2008, 5 (11): : 596 - 597
  • [5] Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis
    Akbar, Ayesha
    Arnott, Ian
    Kennedy, Nicholas A.
    Nolan, Jonathan
    Peake, Simon
    Whiteoak, Simon R.
    Probert, Chris
    Fraser, Aileen
    Cheshire, Alex
    Lewis, Allyson
    Sugrue, Kathleen
    Laird, Susan
    Scott, Glyn
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2021, 82 (10)
  • [6] A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis
    Hawkey, CJ
    Dube, LM
    Rountree, LV
    Linnen, PJ
    Lancaster, JF
    Krejs, GJ
    Gangl, A
    VanTrappen, G
    Barbier, F
    Poleski, M
    Martin, F
    Saibil, F
    RaskMadsen, J
    Lauritsen, K
    Barbier, JP
    Rambaud, JC
    Couturier, D
    Caspary, WF
    Goebell, H
    Doelle, W
    Strohmeyer, G
    Swobodnik, W
    Raedler, A
    Skandalis, N
    vanDeventer, SJH
    Snel, P
    Wright, JP
    Gessull, MA
    Gonzales, F
    Obrador, A
    Halter, F
    Kayasseh, L
    OMorain, C
    Rees, WO
    GASTROENTEROLOGY, 1997, 112 (03) : 718 - 724
  • [7] Mesalazine dose modification based on fecal calprotectin levels in ulcerative colitis patients in clinical remission
    Pinero, G. S.
    Manosa, M.
    Canete, F.
    Calafat, M.
    Gonzalez, L.
    Ruffinengo, O.
    Domenech, E.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 557 - 558
  • [8] Comparison of Mesalazine and Balsalazide in Induction and Maintenance of Remission in Patients with Ulcerative Colitis: A Meta-Analysis
    Roja Rahimi
    Shekoufeh Nikfar
    Ali Rezaie
    Mohammad Abdollahi
    Digestive Diseases and Sciences, 2009, 54 : 712 - 721
  • [9] Disposition of 5-ASa by olsalazine (Dipentum) and mesalazine (Asacol) in patients with ulcerative colitis in remission
    Archimandritis, A
    Hatzis, G
    Konstandinidis, A
    Paraskeva, K
    Tjivras, M
    Skandalis, N
    GASTROENTEROLOGY, 1997, 112 (04) : A924 - A924
  • [10] Comparison of Mesalazine and Balsalazide in Induction and Maintenance of Remission in Patients with Ulcerative Colitis: A Meta-Analysis
    Rahimi, Roja
    Nikfar, Shekoufeh
    Rezaie, Ali
    Abdollahi, Mohammad
    DIGESTIVE DISEASES AND SCIENCES, 2009, 54 (04) : 712 - 721
12345